Spectrum Pharmaceuticals Announces Satraplatin Data Presentation At The American Society Of Clinical Oncology Prostate Cancer Symposium

Sat, 24 Feb 2007 02:00 PM EST

... Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that final progression-free survival (PFS) results for the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer), a double-blind, randomized Phase 3 registrational trial, will be presented today at the ASCO Prostate Cancer Symposium in Orlando, Florida. [click link for full article] ...